astrazeneca hit drug failure
shares drug closed uk trade failure iressa drug major clinical trial
lung cancer drug prolong survival patients disease setback rejection october pill exanta major money spinners cholesterol drug crestor facing mounting safety concerns blockbuster drugs meant power company forward failing risks crestor nick turner analyst brokers jefferies
astrazeneca hoped pitch iressa drug rival medicine tarceva iressa proved placebo extending lives trial involving patients tarceva osi pharmaceuticals genentech roche proved successful helping prolong lung cancer patients aztrazeneca appointed executive director board john patterson charge drug development company patterson substantial clinical organisation processes determined improve development regulatory performance restore confidence company shareholders chief executive tom mckillop
